Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
31 Idiopathic Pulmonary Fibrosis Trials
Power is an online platform that helps thousands of Idiopathic Pulmonary Fibrosis patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis
Columbus, OhioStudy RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40+
Sex:All
576 Participants Needed
BI 1015550 for Pulmonary Fibrosis
Columbus, OhioThis study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550 (study 1305-0014 or 1305-0023).
The goal of this study is to find out how well people with pulmonary fibrosis tolerate long- term treatment with nerandomilast. The study also tests whether nerandomilast improves lung function and prolongs the time until symptoms get worse, participants need to go to the hospital, or die.
Every participant takes nerandomilast as tablets for up to 1 year and 10 months. The participants may also continue their regular treatment for pulmonary fibrosis during the study.
Participants visit their doctors regularly. During these visits, the doctors collect information on any health problems of the participants. Participants also regularly do lung function tests.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Suicidality, Severe Depression, Malignant Neoplasm, Others
Must Be Taking:Nerandomilast
1700 Participants Needed
Inhaled Treprostinil for Pulmonary Fibrosis
Columbus, OhioStudy RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, IPF, Uncontrolled Cardiac Disease, Others
Must Be Taking:Nintedanib, Pirfenidone
698 Participants Needed
N-acetyl Cysteine for Idiopathic Pulmonary Fibrosis
Columbus, OhioThe purpose of this study is to compare the effect of n-acetylcysteine (NAC) plus standard care with matched placebo plus standard of care in patients diagnosed with idiopathic pulmonary fibrosis (IPF) who have the TOLLIP rs3750920 TT genotype. The study will compare the time to a composite endpoint of relative decline in lung function \[10% relative decline in forced vital capacity (FVC), first respiratory hospitalization, lung transplantation, or all-cause mortality\]
The secondary objectives will be to examine the effect of NAC on the components of the primary composite endpoint, the rates of clinical events, change in physiology, change in health status, and change in respiratory symptoms.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40+
Sex:All
202 Participants Needed
BMS-986278 for Pulmonary Fibrosis
Columbus, OhioThe purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:21+
Sex:All
Key Eligibility Criteria
Disqualifiers:Idiopathic Pulmonary Fibrosis, Stroke, Heart Failure, Current Malignancy, Others
Must Not Be Taking:Systemic Corticosteroids
1092 Participants Needed
BMS-986278 for Idiopathic Pulmonary Fibrosis
Columbus, OhioThe purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:40+
Sex:All
Key Eligibility Criteria
Disqualifiers:Stroke, Heart Failure, Malignancy, Others
Must Be Taking:Pirfenidone, Nintedanib
1185 Participants Needed
Inhaled Treprostinil for Pulmonary Fibrosis
Columbus, OhioStudy RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Age:40+
Sex:All
792 Participants Needed
AP01 for Pulmonary Fibrosis
Cincinnati, OhioA randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Idiopathic Pulmonary Fibrosis, Renal Disease, Others
Must Be Taking:Nintedanib
300 Participants Needed
Bexotegrast for Idiopathic Pulmonary Fibrosis
Cincinnati, OhioThis trial is testing a new medication called bexotegrast to see if it can help people with a lung disease called idiopathic pulmonary fibrosis (IPF). The study will include people who are already on other treatments as well as those who are not. The goal is to find out if bexotegrast can improve lung function and slow down the disease.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:40+
Sex:All
360 Participants Needed
LYT-100 for Idiopathic Pulmonary Fibrosis
Cincinnati, OhioThis trial tests LYT-100, a new drug, in adults aged 40+ with Idiopathic Pulmonary Fibrosis who haven't been treated before. It aims to see if the drug can slow down the decline in lung function.
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:40+
Sex:All
240 Participants Needed
HZN-825 for Idiopathic Pulmonary Fibrosis
Cleveland, OhioThis trial tests HZN-825, a new oral medicine, in people with Idiopathic Pulmonary Fibrosis (IPF). The goal is to see if it can help by blocking a receptor that causes lung scarring. The study will check its safety and effectiveness over several months.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 80
Sex:All
153 Participants Needed
Vixarelimab for Pulmonary Fibrosis
Muncie, IndianaThis trial is testing vixarelimab, a medication that may help improve lung function, in people with IPF and SSc-ILD. It works by reducing inflammation and scarring in the lungs to help with breathing.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Lung Transplant, Malignancy, Immunodeficiency, Others
Must Be Taking:Pirfenidone, Nintedanib, Tocilizumab
320 Participants Needed
Buloxibutid for Pulmonary Fibrosis
Cleveland, OhioThe ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF.
Trial website: www.aspire-ipf.com
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:40+
Sex:All
Key Eligibility Criteria
Disqualifiers:Malignancy, Airways Obstruction, Liver Disease, Others
Must Be Taking:Licensed IPF Therapy
270 Participants Needed
This is a multi-center randomized, double-blind, placebo-controlled, parallel, 4-arm study of nalbuphine ER (NAL ER).
After meeting eligibility during the Screening Period, subjects will be randomized (1:1:1:1) to one of four treatment arms with placebo and increasing doses of nalbuphine ER. Each arm will be titrated to their fixed dose during the blinded 2-week Titration period followed by the 4-week Fixed Dose Period for a total of 6 weeks on drug.
For more information see the country specific approved websites:
Germany, Netherlands, Poland, Spain, Italy, Chile: TheCoralTrial.com United Kingdom, Australia, Canada: CoralCoughTrial.com Turkey: please refer to the list of locations and reach out to the site directly
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Sleep Apnea, Psychiatric Disorder, Substance Abuse, Others
Must Not Be Taking:Opiates, Benzodiazepines, MAOIs, Others
160 Participants Needed
ENV-101 for Pulmonary Fibrosis
Ann Arbor, MichiganThe goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in this patient population.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:40+
Sex:All
Key Eligibility Criteria
Disqualifiers:Smoking, Malignancy, Hepatic Impairment, Others
Must Be Taking:Antifibrotics, Immunosuppressants
200 Participants Needed
GSK3915393 for Pulmonary Fibrosis
Ann Arbor, MichiganIdiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time. The study will assess the safety and effectiveness of GSK3915393 in IPF participants.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Interstitial Lung Disease, Autoimmune Diseases, Others
Must Be Taking:Antifibrotics
150 Participants Needed
Lung and Bone Marrow Transplant for Pulmonary Fibrosis
Pittsburgh, PennsylvaniaThe purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore hematologic function.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 60
Sex:All
Key Eligibility Criteria
Disqualifiers:Malignant Conditions, HIV, Uncontrolled Infections, Others
Must Not Be Taking:Live Vaccines
8 Participants Needed
DWN12088 for Idiopathic Pulmonary Fibrosis
Pittsburgh, PennsylvaniaThis trial is testing a new drug called DWN12088 to see if it can help people with Idiopathic Pulmonary Fibrosis, a serious lung disease. The study will check if the drug is safe and effective. The exact way the drug works is not detailed, but it aims to improve lung function or slow down the disease.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:40+
Sex:All
Key Eligibility Criteria
Disqualifiers:Acute IPF Exacerbation, Smoking, Pregnancy, Others
Must Be Taking:Pirfenidone, Nintedanib
102 Participants Needed
EGCG for Pulmonary Fibrosis
Ann Arbor, MichiganThis trial is testing EGCG, a compound from green tea, in patients with idiopathic pulmonary fibrosis (IPF). The goal is to see if EGCG can safely reduce lung scarring. EGCG works by blocking harmful signals that cause lung tissue to harden. Epigallocatechin-3-gallate (EGCG) is a polyphenol and a major component of green tea, known for its potent antioxidant, anti-inflammatory, and anti-fibrotic properties.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:40 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:HCV, HBV, Emphysema, Alcohol, Others
Must Be Taking:Nintedanib, Pirfenidone
50 Participants Needed
EGCG for Pulmonary Fibrosis
Ann Arbor, MichiganThe primary purpose of this substudy is to determine if collagen-targeted PET using the type 1 collagen-targeted PET probe, Gallium-68 (68Ga)-labeled collagen binding probe 8 (CBP8) can inform as to drug effect of EGCG and assist in dose selection.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:40 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Radiation Exposure, Implants, Others
22 Participants Needed
Ifetroban for Pulmonary Fibrosis
Indianapolis, IndianaIfetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:40 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Pulmonary Abnormalities, Cardiovascular Diseases, Others
Must Be Taking:Antifibrotics, Pulmonary Hypertension Monotherapy
128 Participants Needed
BI 1819479 for Pulmonary Fibrosis
Warren, MichiganThis study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment for IPF are on stable treatment for at least 3 months before starting the study. The purpose of this study is to find out whether a medicine called BI 1819479 helps people with IPF. 3 different doses of BI 1819479 are tested in this study.
Participants are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1819479. Participants in 1 group get placebo. Placebo tablets look like BI 1819479 tablets, but do not contain any medicine. Participants take the treatment for 6 months to 1 year. Participants are in the study for up to 1 year and 2 months. During this time, they visit the study site between 10 and 12 times and get up to 11 phone calls from the site staff.
At site visits doctors regularly perform breathing tests that measure how well the lungs are working. Researchers compare the results between participants who take BI 1819479 and placebo. The doctors also regularly check participants' health and take note of any unwanted effects.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:40+
Sex:All
Key Eligibility Criteria
Disqualifiers:Acute IPF Exacerbation, Significant Disease, Others
Must Be Taking:Nintedanib, Pirfenidone
300 Participants Needed
BI 1839100 for Pulmonary Fibrosis
Warren, MichiganAdults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can participate in this study. Only people who have a chronic cough can take part. The purpose of this study is to find out how well BI 1839100 helps reduce coughing in people with IPF or PPF.
Participants who have IPF are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1839100. Participants in 1 group get placebo. Placebo looks like BI 1839100 but does not contain any medicine. Participants take the treatment for 3 months. After 1 month of treatment, participants who take the highest dose will have coughing measured to find out if the medicine works. If it does not work, the study may be stopped. Participants who have IPF are in the study for slightly longer than 4 months. During this time, they visit the study site 7 times. This study will also measure the effects of BI 1839100 on coughing and lung function in a smaller group of people with PPF.
During the study, coughing is measured over 24 hours about once per month using a portable device given to participants to use during the study. Participants fill in questionnaires about their coughing. Doctors also perform breathing tests that measure how well the lungs are working at the site visits. Researchers compare the results between participants who take BI 1839100 and placebo. The doctors also regularly check participants' health and take note of any unwanted effects.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Acute Exacerbation, Reversible Airflow, Chronic Infection, Others
Must Be Taking:Nintedanib, Pirfenidone, Immunomodulatory
230 Participants Needed
TTI-101 for Idiopathic Pulmonary Fibrosis
Chicago, IllinoisThe primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:40+
Sex:All
Key Eligibility Criteria
Disqualifiers:Respiratory Infections, Surgery, Cardiac Disorders, Others
Must Be Taking:Nintedanib
75 Participants Needed
Hyperpolarized Xenon-129 MRI for Idiopathic Pulmonary Fibrosis
Charlottesville, VirginiaIdiopathic pulmonary fibrosis has a poor prognosis with limited treatment options. The Investigator hypothesize hyperpolarized Xe129-MRI can be performed in patients with IPF and repeated over time which will detect deficiencies related to perfusion in the lung.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Early Phase 1
Age:18+
Sex:All
6 Participants Needed
High Oxygen Delivery for Idiopathic Pulmonary Fibrosis
Hamilton, OntarioThe purpose is to determine if patients with idiopathic pulmonary fibrosis (IPF) taking nintedanib will have improved exercise endurance, breathlessness and quality of life if breathing 60% oxygen compared to standard of care during an 8 week exercise training program.
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:19+
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiovascular, Musculoskeletal, Neurological, Others
Must Be Taking:Nintedanib
88 Participants Needed
BBT-877 for Idiopathic Pulmonary Fibrosis
Chicago, IllinoisThis is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy, safety, and tolerability of 200 mg twice daily (BID) of BBT-877 in patients with IPF, with or without AF approved background therapies (pirfenidone or nintedanib).
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:40+
Sex:All
129 Participants Needed
GRI-0621 for Pulmonary Fibrosis
Winston Salem, North CarolinaThis is a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study. Approximately 36 subjects with IPF will be randomized in a 2:1 ratio for GRI-0621 4.5mg or Placebo. GRI-0621 dose of 4.5mg will be compared with placebo following once daily oral administration for 12 weeks.
Concurrently, a Sub-Study will be conducted, examining the number and activity of NKT cells in BAL, for up to 12 eligible subjects (across various centers).
An early-stage patient variability assessment will be completed when 12 subjects have completed 2 weeks of treatment. Followed by an interim analysis performed when 24 subjects complete 6 weeks of treatment.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:40 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Emphysema, Coronary Artery Disease, Others
Must Not Be Taking:CYP2C8 Inhibitors, CYP2C8 Inducers
36 Participants Needed
INS018_055 for Idiopathic Pulmonary Fibrosis
Winston-Salem, North CarolinaThis trial tests a new oral medication, INS018_055, in adults with Idiopathic Pulmonary Fibrosis (IPF). It aims to see if the medication is safe and well-tolerated over a few months.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:40+
Sex:All
Key Eligibility Criteria
Disqualifiers:Acute IPF Exacerbation, Smoking, Pregnancy, Others
Must Be Taking:Antifibrotics
60 Participants Needed
Idiopathic pulmonary fibrosis (IPF) is a lung disease that limits the ability to breathe enough for a good workout. One way to improve the exercise training is to reduce the number of muscles being trained together. By training one leg at a time, the patient does not have to breathe as much allowing each leg a better workout. Our groundwork suggests it may work in patients with IPF. This study will help decide whether one-legged exercise training is better at improving a patient's exercise endurance compared to the usual way of exercising with both legs at the same time.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Comorbidities, Recent Exacerbation, Others
50 Participants Needed
Page 1 of 2+
Frequently Asked Questions
How much do Idiopathic Pulmonary Fibrosis clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Idiopathic Pulmonary Fibrosis clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Idiopathic Pulmonary Fibrosis trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Idiopathic Pulmonary Fibrosis is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Idiopathic Pulmonary Fibrosis medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Idiopathic Pulmonary Fibrosis clinical trials ?
Most recently, we added Hymecromone for Interstitial Lung Disease, Hyperpolarized Xenon-129 MRI for Idiopathic Pulmonary Fibrosis and Buloxibutid for Pulmonary Fibrosis to the Power online platform.